a2 Milk is one of New Zealand’s premier export brands. After a dream run, its share price has dropped sharply. Is it still worth buying into?
For the past decade, the New Zealand stock market has been a “rock star”. Therefore, some Kiwi investors have reaped the benefits.
Over the past decade many would have seen some of the companies on the NZ stock market that blossomed.
Two of these companies were A2 Milk and Xero.
At Wealth Morning it is our mission to try to understand why it’s grown and to forecast whether or not investors can expect it to continue.
We’ll analyze big and small companies listed on the NZ Stock Market.
Also the macro market as well as individual stocks and unveil any opportunities for you as an investor.
It’s a promising New Zealand small-cap company you may not have heard of. Here’s why this brand is inspiring fierce loyalty around the world.
Small-cap investing is about embracing both risk and potential. Here are two promising Kiwi stocks worth taking a closer look at.
Auckland International Airport is the main gateway into New Zealand. Amidst Covid fear, is it still worth buying into?
It’s a potential deal that’s gotten tongues wagging. AustralianSuper is making a takeover bid for Kiwi infrastructure company Infratil.
These IPOs appear to be popular and attractive. But hold your horses. You shouldn’t invest in them until you read our urgent analysis.
As fear recedes, greed surges. The world is already looking beyond Covid, but we would be wise to prepare for the next global risk event.
In times of turbulence, it’s important to keep your emotions in check. That’s the secret of being an effective investor.
It’s the money secret no one told you about. Here’s how you could boost your return by over 50% by using this age-old technique.
The shock arrival of Covid-19 was the first black swan event of 2020. But did you know about the second black swan, which was more important?
The global retail market is huge, recording over US$20 trillion in sales annually. Is it time to capture a slice of it?
It’s the glorious moment we’ve all been waiting for. Pfizer has announced vaccine success in its first interim Phase 3 study.